Endocrine tumours of the pancreas: An update

Australian and New Zealand Journal of Surgery

Volumn 68, Issue 2, 1998, Pages 90-100

  Proye, Charles A G ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Endocrine tumour; Gastrinoma; Insulinoma; Localization; Pancreas; Somatostatin; Surgery; Vipom a

Indexed keywords

SOMATOSTATIN;

DIAGNOSTIC APPROACH ROUTE; GASTRINOMA; HYPERINSULINISM; INSULINOMA; PANCREAS ISLET CELL HYPERPLASIA; PANCREAS ISLET CELL TUMOR; REVIEW; TREATMENT PLANNING; TUMOR LOCALIZATION; VIPOMA;

EID: 0031748923     PISSN: 00048682     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-2197.1998.tb04714.x     Document Type: Review

References (150)

1. Larsson LI. Two distinct types of islet abnormalities associated with endocrine pancreatic tumours. Virchows Arch. A Pathol. Anal. Histopathol. 1977; 376: 209-19.
2. Goudswaard WB, Houthoff HJ, Koudstaal J, Zwierstra RP. Nesidioblastosis and endocrine hyperplasia of the pancreas: A secondary phenomenon. Hum. Pathol. 1986; 17: 46-54.
3. Thompson GB, Service FJ, Van Heerden JA et al. Reoperative insulinomas, 1927-1992: An institutional experience. Surgery 1993; 114: 1196-206.
4. Harness JK, Geelhoed GW, Thompson NW et al. Nesidioblastosis in adults. A surgical dilemma. Arch. Surg. 1981; 116: 575-80.
5. Harrison TS, Fajans SS, Floyd JC et al. Prevalence of diffuse pancreatic beta cell islet disease with hyperinsulinism. Problems in recognition and management. World J. Surg. 1984; 8: 583-9.
6. Fukimutsu M, Tanaka K, Yokota K, Tanaka Y, Fukunari N, Hayakawa K. Localized pancreatic cell hyperplasia without tumor lesions in an adult who displayed hyperinsulinemia. 35th World Congress of Surgery, Hong Kong, August 1993; A 825.
7. Taylor SJ. Hypoglycemia associated with antibodies to the insulin receptor. N. Engl. J. Med. 1982; 307: 1422-6.
8. Boissel P, Proye C. Les tumeurs endocrines du pancréas. Rapport au 87th Congrès de l'AFC Masson-Ed-Paris 1985.
9. Van Heerden JA, Grant CS, Czako PF, Service J, Charbonneau JW. Occult functioning insulinomas: Which localizing studies are indicated? Surgery 1992; 112: 1010-15.
10. Bottger TC, Junginger T. Is preoperative radiographic localization of islet cell tumors in patients with insulinoma necessary? World J. Surg. 1993; 17: 427-32.
11. Norton JA, Shawker TH, Doppman et al. Localization and surgical treatment of occult insulinomas. Ann. Surg. 1990; 212: 615-20.
12. Zeiger MR, Shawker TH, Norton JA. Use of intraoperative ultrasonography to localize islet cell tumors. World J. Surg. 1993; 17: 448-54.
13. Norton JA, Cromack DT, Shawker TH et al. Intraoperative ultrasonographic localization of islet cell tumors. Ann. Surg. 1988; 207: 160-8.
14. Grimelius L, Hultquist GT, Stenkvist B. Cytological differentation of asymptomatic pancreatic islet cell tumours in autopsy material. Virchows Arch. A Pathol. Anat. Histopathol. 1975; 365: 275-88.
15. Kimura W, Kuroda A, Moriora Y. Clinical pathology of endocrine tumors of the pancreas: Analysis of autopsy cases. Dig. Dis. Sci. 1991; 36: 933-42.
16. Imamura M, Takahashi K. Use of selective arterial secretin injection test to guide surgery in patients with Zollinger-Ellison sydrome. World J. Surg. 1993; 17: 433-8.
17. Imamura M, Takahashi K, Isobe Y, Hattori Y, Satomura K, Tobe T. Curative resection of multiple gastrinomas aided by selective arterial secretin injection test and intraoperative secretin test. Ann. Surg. 1989; 210: 710-18.
18. Doppman JL, Miller DL, Chang R, Shawker TH, Gorden P, Norton JA. Insulinomas: Localization with selective intraarterial injection of calcium. Radiology 1991; 178: 237-41.
19. Doppman JL. Pancreatic endocrine tumors: The search goes on. N. Engl. J. Med. 1992; 326: 1770-2.
20. Doppman JL, Miller DL, Chang R, Gorden P, Eastman RC, Norton JA. Intraarterial calcium stimulation test for detection of insulinomas. World J. Surg. 1993; 17: 439-43.
21. Doppman JL, Chang, Fraker DL et al. Localization of insulinomas to regions of the pancreas by intraarterial stimulation with calcium. Ann. Intern. Med. 1995; 123: 269-73.
22. Rosch T, Lightdale CJ, Botet JF et al. Localization of pancreatic-endocrine tumors by endoscopic ultrasonography. N. Engl. J. Med. 1992; 326: 1721-6.
23. Krenning EP, Bakker WH, Breeman WAP et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; 4: 242-4.
24. Amouyal P, Gerosa Y, Amouyal G et al. Apport de l'echoendoscopie dans le diagnostic topographique des insulinomes. Résultats définitifs d'une étude prospective et multicentrique. Gastroenterol. Clin. Biol. 1993; 17: A2-51.
25. Palazzo L, Roseau G, Chaussade S, Salmeron M, Gaudric M, Paolaggi JA. Tumeurs endocrines pancréatiques: Apport de l'echoendoscopie au diagnostic de localisation. Ann. Chir. 1993; 47: 419-24.
26. Palazzo L, Borotto E, Napoleon B et al. Valeur de l'echo endoscopie dans le diagnostic de localisation des tumeurs endocrines pancréatiques et duodénales chez les malades atteints de néoplasie endocrinienne multiple. Gastroenterol. Clin. Biol. 1994; 18: A2-70.
27. Thompson NW, Czako PF, Fritts LL et al. Role of endoscopic ultrasonography in the localization of insulinomas and gastrinomas. Surgery 1994; 116: 1131-8.
28. Ruszniewski P, Amouyal P, Amouyal G, Cadiot G, Mignon M, Bernades P. Valeur diagnostique de l'echoendoscopie (EES) pour la localisation des gastrinomes. Gastroenterol. Clin. Biol. 1993; 17: A52.
29. Ruszniewski P, Amouyal P, Amouyal G et al. Localization of gastrinomas by endoscopic ultrasonography in patients with the Zollinger-Ellison syndrome. Surgery 1995; 117: 629-35.
30. Baudin E, Schlumberger M, Lumbroso J et al. Fixation de l'octreotide marqué en cas de tumeurs neuro-endocrines: facteur prédictif de differentiation tumorale Ann. Endocr. 1994; 55: 72-118.
31. Van Eyck CHJ, Bruining HA, Reubi JC et al. Use of isotopic-labeled somatostatin analogs for visualization of islet-cell tumors. World J. Surg. 1993; 17: 444-7.
32. Barton JC, Hirschowitz BI, Maton PN, Jensen RT. Bone metastases in malignant gastrinoma. Gastroenterology 1986; 91: 1179-85.
33. Schirmer WJ, Melvin WS, Rusch RM et al. Indium-111 pentitreotide scanning vs. conventional imaging techniques for the localization of gastrinoma. Surgery 1995; 118: 1105-14.
34. Cadiot G, de Kerviler E, Le Guludec D, Camhaji B, Ruszniewski B, Mignon M. Scintigraphie des recepteurs de la somatostatine dans le syndrome de Zollinger-Ellison (SZE). Gastroenterol. Clin. Biol. 1993; 17: A2.
35. Cadiot G, De Kerviler E, Lebtahi R, Le Guludec D, Mignon M. Chez quels malades atteints d'un syndrome de Zollinger-Ellison (SZE), la scintigraphie des recepteurs de la somatostatine (SRS) est-elle utile? Gastroenterol. Clin. Biol. 1994; 18: A15.
36. Virgolini I, Raderer M, Kurtaran et al. Vasointestinal peptid receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N. Engl. J. Med. 1994; 331: 1116-21.
37. Schirmer WJ, O'Dorsio TM, Schirmer TP, Mojzisik CM, Hinkle GH, Martin EW. Intraoperative localization of neuroendocrine tumors with 125-I-TYR (3)-octreotide and a hand-held gamma detecting probe. Surgery 1993; 114: 745-52.
38. Woltenng EA, Barrie R, O'Dorsio TM, O'Dorsio MS, Nance R, Cook DM. Detection of occult gastrinomas utilizing 125 I labelled lanreotide and intraoperative gamma detection. Surgery 1994; 116: 1139-47.
39. Frucht H, Norton JA, London JF et al. Detection of duodenal gastrinomas by operative endoscopie transillumination. Gastroenterology 1990; 99: 1622-7.
40. Sugg S, Norton JA, Fruker DL et al. A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann. Surg. 1993; 218: 138-44.
41. Parneix M, Rullier E, Gin H, Roche A. Apport du pancréas artificiel dans le diagnostic et le traitement chirurgical des insulinomes. Ann. Chir. 1994; 48: 421-9.
42. Howard TJ, Sawicki MP, Stabile B, Watt PC, Passaro E. Biologic behavior of sporadic gastrinoma located to the right and left of the superior mesenteric artery. Am. J. Surg. 1993; 165: 101-5.
43. Thompson NW, Vinik AI, Eckhauser FE. Microgastrinomas of the duodenum. Ann. Surg. 1989; 209: 396-403.
44. Thom AK, Norton JA, Axiotis CA, Jensen RT. Location, incidence and malignant potential of duodenal gastrinomas. Surgery 1991; 110: 1086-93.
45. Imamuru M, Kanda M, Takahashi K et al. Clinicopathological characteristics of duodenal microgastrinornas. World J. Surg. 1992; 16: 703-10.
46. Miyata M, Nakao K, Saramoto T et al. Removal of mesenteric gastrinoma: A case report. Surgery 1986; 99: 245-8.
47. Ellison EC. Forty year appraisal of gastrinoma. Back to the future. Ann. Surg. 1995; 222: 511-24.
48. Oberhelman HA. JV in discussion of outcome of lymph node involvement in patients with the Zollinger-Ellison syndrome. Ann. Snrg. 1988; 208: 291-8.
49. Lasson A, Alwmark A, Nobin A, Sundler F. Endocrine tumors of the duodenum. Ann. Surg. 1983; 197: 393-8.
50. Thompson JC in Delcore R, Cheung LY, Friesen SR. Outcome of lymph node involvement in patients with the Zollinger-Ellison sydrome. Ann. Surg. 1988; 208: 291-8.
51. Thompson NW, Pasieka J, Fukuuchi A. Duodenal gastrinomas, duodenotomy and duodenal exploration in the surgical management of Zollinger-Ellison syndrome. World J. Surg. 1993; 17: 455-62.
52. Jaffe BM. Current issues in the management of Zollinger-Ellison syndrome. Surgery 1992; 111: 241-3.
53. Pipeleers-Marichal M, Somers G et al. Gastrinomas in the duodenum of patients with multiple endocrine neoplasia type I and the Zollinger-Ellison syndrome. N. Engl. J. Med. 1990; 322: 723-7.
54. Pipeleers-Marichal M, Donow C, Heitz PU, Klöppel G. Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type I. World J. Surg. 1993; 17: 481-8.
55. Maton PN. The management of Zollinger-Ellison syndrome. Aliment. Pharmacol. Ther. 1993; 7: 467-75.
56. Arnold WS, Fraker DL, Alexander RH, Weber HC, Norton JA, Jensen RT. Apparent lymph node primary gastrinoma. Surgery 1994; 116: 1123-30.
57. Cocco AK, Conway SJ. Zollinger-Ellison syndrome with ovarian mucinous cyst adenocarcinoma. N. Engl. J. Med. 1975; 293: 485-6.
58. Primrose JN, Maloney M, Wells M, Bulgim O, Johnston D. Gastrin-producing ovarian mucinous cystadenomas. A cause of the Zollinger-Ellison syndrome. Surgery 1988; 104: 830-3.
59. Bornman PC, Marks IN, Mee AS, Price S. Favourable response to conservative surgery for extra-pancreatic gastrinoma with lymph-node metastases. Br. J. Surg. 1987; 74: 198-201.
60. Delcore R, Hermreck AS, Friesen SR. Selective surgical management of correctable hypergastrinemia. Surgery 1989; 106: 1094-102.
61. Eckhauser FE in Delcore R, Cheung LY, Friesen SR. Outcome of lymph node involvement in patients with the Zollinger-Ellison syndrome. Ann. Surg. 1988; 208: 291-8.
62. Preisen SR. Are 'aberrant nodal gastrinomas' pathogeneticaliy similar to 'lateral aberrant thyroid' nodules? Surgery 1990; 107: 236-8.
63. McGillivray DC, Rushin JM, Zeiger MA, Shakir KMM. The significance of gastrinomas found in peripancreatic lymph nodes. Surgery 1991; 109: 558-62.
64. Perrier ND, Batts KP, Thompson GB, Grant CS, Plummer TB. An immunohistochemical survey for neuroendocrine cells in regional pancreatic lymph nodes: A plausible explanation for primary nodal gastrinomas? Surgery 1995; 118: 957-8.
65. Goletti O, Chairugi M, Buccianti P et al. Resection of liver gastrinoma leading to persistent engastrinemia. Eur. J. Surg. 1992; 158: 55-7.
66. Terada T, Nakanuma Y, Kakita A. Pathologic observations of intrahepatic peribiliary glands in 1000 consecutive autopsy livers: Heterotopic pancreas in the liver. Gastroenterology 1990; 98: 1333-7.
67. Zollinger RM, Ellison EC, O'Dorsio TM, Sparrs J. Thirty years' experience with gastrinoma. World J. Surg. 1984; 8: 427-35.
68. Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome. Ann. Surg. 1992; 215: 8-18.
69. Howard TJ, Zinner MJ, Stabile BE, Passaro E. Gastrinoma excision for cure. A prospective analysis. Ann. Surg. 1990; 211: 9-14.
70. Farley DR, Van Heerden JA, Grant S, Miller LT, Ilstrup DM. The Zollinger-Ellison syndrome: A collective surgical experience. Ann. Surg. 1992; 215: 561-70.
71. Grama D, Eriksson B, Martensson H et al. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J. Surg. 1992; 16: 632-9.
72. Norton JA, Cornelius MJ, Doppman JL, Maton PN, Gardner JD, Jensen RT. Effect of parathyroidectomy in patients with hyperparathyroidism and Zollinger-Ellison syndrome (ZES) in the setting of MEN. A prospective study. Surgery 1987; 102: 958.
73. Mignon M, Ratzui V. Medizinische Behandlung von sporadischen und familiären gastrinomen: Eine aktuelle strategie und ihre grenzen Acta Chir. Austr. 1992; 24: 76-81.
74. Mignon M, Ruszniewski P, Podevin P, Sabbagh L, cadiot G, Rigaud D, Bonfils S. Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type I. World J. Surg. 1993; 17: 489-97.
75. Mignon M, Jensen RT. Endocrine Tumors of the Pancreas. Recent Advances in Research and Management. Basel: Karger, 1995.
76. McFarlane MP, Fraker DL, Alexander HR, Norton JA, Lubensky I, Jensen RT. Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. Surgery 1995; 118: 973-80.
77. Norton JA, Jensen RT. Unresolved surgical issues in the management of patients with Zollinger-Ellison syndrome. World J. Surg. 1991; 15: 151-9.
78. Sheppard BC, Norton JA, Doppman JL, Maton PN, Gardner JD, Jensen RT. Management of islet cell tumors in patients with multiple endocrine neoplasia: A prospective study. Surgery 1989; 106: 1108-18.
79. Thompson NW, Bondeson AG, Bondeson L, Vinik A. The surgical treatment of gastrinoma in MEN I syndrome patients. Surgery 1989; 106: 1081-6.
80. Thompson NW. Die chirurgische therapie des Zollinger-Ellison syndroms bei sporadischen und MEN I patienten. Acta Chir. Austr. 1992; 24: 82-7.
81. Grama D, Skoggeid B, Wilander E et al. Pancreatic tumors in multiple endocrine neoplasia type 1: Clinical presentation and surgical treatment. World J. Surg. 1992; 16: 611-19.
82. Skogseid B, Oberg K, Ericsson B et al. Surgery of asymptomatic pancreatic lesion in multiple endocrine neoplasia type 1. World J. Surg. 1996; 20: 872-6.
83. Thompson NW, Lloyd RV, Nishiyama RH et al. MEN I pancreas: A histological and immunohistochemical study. World J. Surg. 1984; 8: 561-74.
84. Delcore R, Friesen SR. Role of pancreatoduodenectomy in the management of primary duodenal wall gastrinomas in patients with Zollinger-Ellison syndrome. Surgery 1992; 112: 1016-23.
85. Stadil F, Bardram L, Gustafsen J, Efsen F. Surgical treatment of the Zollinger-Ellison syndrome. World J. Surg. 1993; 17: 463-7.
86. Metz DC, Pisegna JR, Fishbeyn A, Benya RV, Jensen RT. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J. Surg. 1993; 17: 469-80.
87. Pisegna JR, Norton JA, Slimak GG et al. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 1992; 102: 767-78.
88. McEntee GP, Nagorney DM, Kvole LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108: 1091-6.
89. Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic tumors. Surgery 1992; 112: 1024-32.
90. Grant CS. Surgical management of malignant islet-cell tumors. World J. Surg. 1993; 17: 498-503.
91. Melvin WS, Johnson JA, Sparks J, Innes JT, Ellison EC. Long-term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia. Surgery 1993; 114: 1183-8.
92. Wilson S. Zollinger-Ellison syndrome in children: A 25 year follow-up. Surgery 1991; 110: 696-703.
93. Friesen SR. Update on the diagnosis and treament of rare neuroendocrine tumors. Surg. Clin. North Am. 1987; 67: 379-93.
94. Jaffe BM. The diarrheogenic syndrome: Verner-Morrison or Vipoma syndrome. In: Friesen SR, Thompson NW (eds). Surgical Endocrinology. Philadelphia: Lippincott, 1990; 293-310.
95. Maton PN. Use of octreotide acetate for control of symptoms in patients with islet cell tumors. World J. Surg. 1993; 17: 504-10.
96. Kraenzlin ME, Ch'ng JLC, Wood SM, Carr DH, Bloom SR. Long term treatment of a vipoma with somatostatin analogue resulting in remission of symptoms and possible shrinking of metastases. Gastroenterology 1985; 88: 185-7.
97. Elias E, Polak JM, Bloom SR et al. Pancreatic cholera due to production of gastric inhibitory polypeptide. Lancet 1972; 2: 791-3.
98. Bloom SR, Christofides ND, Delamarter J, Kawashima E, Polak JM. Diarrhoea in vipoma patients associated with co-secretion of a second active peptide (peptide histidine isolencine) explained by single coding gene. Lancet 1983; 2: 1163-5.
99. Munn JS, Prinz RA. The diabetes-dermatitis syndrome: Glucagonoma. In: Friesen SR, Thompson NW (eds). Surgical Endocrinology. Philadelphia: Lippincott, 1990; 233-48.
100. Guillauseau PJ, Guillauseau C, Villet R et al. Les glucagonomes. Aspects cliniques biologiques, anatomopathol ogiques et therapeutiques: Revue générale de 130 cas. Gastroenterol. Clin. Biol. 1982; 6: 1029-41.
101. Proye C et al. Tumeurs endocrines du pancréas. Hépatologie 1995; 7: 107A.
102. Proye C, Lefebvre J, Lelievre G et al. Une observation de glucagonome chez une femme de 72 ans: Duodénopancréatectomie céphalique. Résultat à un an et demi. Chirurgie 1980; 106: 600-4.
103. Moattari AR, Cho K, Vinik AI. Somatostatin analogue in treatment of coexisting glucagonoma and pancreatic pseudocyst: Dissociation of responses. Surgery 1990; 108: 581-7.
104. Service FJ, McMahon M, O'brien PC, Ballard DJ. Functioning insulinoma: Incidence, recurrence and long-term survival of patients. A 60 year study. Mayo Clin. Proc. 1991; 66: 711-19.
105. Rothmund M et al. Surgery for benign insulinoma: an international review. World J. Surg. 1990; 14: 393-9.
106. Proye C. Surgical strategy in insulinomas in adults. Acta Chir. Scand. 1987; 153: 481-91.
107. Danforth DN, Gorden P, Brennan MF. Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery 1984; 96: 1027-37.
108. Demeure MJ, Klonoff DC, Karam JH, Duh QY, Clark OH. Insulinomas associated with MEN type I: The need for a different surgical approach. Surgery 1991; 110: 998-1005.
109. O'Riordain DS, O'Brien T, van Heerden JA, Service FJ, Grant CS. Surgical management of insulinoma associated with mulitple endocrine neoplasia type I. World J. Surg. 1994; 18: 488-94.
110. van Boxsom P, Peix JL, Cougard P et al. Les insulinomes pancréatiques dans la néoplasie endocrinienne multiple de type I. Rev. Fr. Endocrinol. Clin. 1995; 36: 105-18.
111. Ganda OP, Weir GC, Soelder JS et al. 'Somatostatinoma': A somatostatin-containing tumour of the endocrine pancreas. N. Engl. J. Med. 1977; 296: 963-7.
112. Partensky C, Champetier P, Sassolas G et al. Retrocession d'une acromégalie après exérèse radicale d'une volumineuse tumeur endocrine bifocale du pancréas. Point de départ de la découverte du facteur de libération de l'hormone de croissance (GRF). Chirurgie 1985; 111: 207-14.
113. Strodel WE, Vinik AI, Lloyd RV et al. Pancreatic polypeptide-producing tumors: Silent lesions of the pancreas? Arch. Surg. 1984; 119: 508-14.
114. Langstein HN, Norton JA, Chiang HCV et al. The utility of circulating levels of human pancreatic polypeptide as a marker for islet cell tumors. Surgery 1990; 108: 1109-16.
115. McLeod MK, Vinik AI. Calcitonin immunoreactivity and hypercalcitoninemia in two patients with sporadic non familial, gastroenteropancreatic neuroendocrine tumors. Surgery 1992; 111: 484-8.
116. Fleury A, Ruszniewski P, Levy P et al. Tumeurs endocrines du pancréas secrétant de la calcitonine. Gastroenterol. Clin. Biol. 1994; 18: B291.
117. Tardio M, Gerard J, Meurisse M et al. Un cas de tumeur endocrine abdominale secrétant de la thyrocalcitonine. Ann. Endocrinol. 1994; 55: 73-119.
118. Benoit R, Metman EH, Bacq Y, Arnoux JP, Fetissof F. Tumeur endocrine pancréatique maligne avec élévation isolée de thyrocalcitoninémie. Apparition secondaire d'un syndrome de Zollinger-Ellison. Gastroenterol. Clin. Biol. 1995; 19: 450-2.
119. Eriksson B, Skoggeid B, Lundquist G, Wide L, Wilander E, Oberg K. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990; 65: 1883-90.
120. Wynick D, Ratcliffe WA, Heath DA, Ball S, Barnard M, Bloom SR. Treatment of a malignant pancreatic endocrine tumour secreting parathyroid hormone related protein. BMJ 1990; 300: 1314-15.
121. Martensson H, Böttcher G, Sundler F, Nobin A. Localization and peptide content of endocrine pancreatic tumors. Ann. Surg. 1990; 212: 607-14.
122. Lamberts SWJ, Tilanus HW, Klooswijk AIJ, Braining HA, van der Lely AJ, de Jong FH. Successful treatment with SMS 201-995 of Cushing's syndrome caused by ectopic adrenocorticotropin secretion from a metastatic gastrin-secreting pancreatic islet cell carcinoma. J. Clin. Endocrinol. Metab. 1988; 67: 1080-3.
123. Belaiche J, Guez C, Marie C, Courillon J, Mallet A, Cattan D. Aspects echographiques et tomodensitometriques des metastases hépatiques des tumeurs endocrines digestives. Gastroenterol. Clin. Biol. 1988; 12: A40.
124. Thompson NW, Eckhauser FE, Vinik AJ, Lloyd RV, Fiddian-Green RG, Strodel WE. Cystic neuroendocrine neoplasia of the pancreas and liver. Ann. Surg. 1984; 199: 158-64.
125. Marrano D, Campione O, Santini D, Piva P, Alberghini M, Casadei R. Cystic insulinoma: A rare islet cell tumour of the pancreas. Eur. J. Surg. 1994; 160: 519-22.
126. Schwartz RW, Munfakh NA, Zweng TN, Strodel WE, Lee E, Thompson NW. Nonfunctioning cystic neuroendocrine neoplasia of the pancreas. Surgery 1994; 115: 645-9.
127. Pyke CM, van Heerden JA, Colby TV, Sarr MG, Weaver AL. The spectrum of serous cystadenoma of the pancreas: Clinical, pathologic and surgical aspects. Ann. Surg. 1992; 215: 132-9.
128. Herebach D, Le Berre N. Tumeurs kystiques et tumeurs endocrines du pancréas: Une association exceptionnelle. Gastroenterol. Clin. Biol. 1994; 18: 6-666.
129. Ohneda A, Otsuki M, Fujiya H. A malignant insulinoma transformated into a glucagonoma syndrome. Diabetes 1979; 28: 962-9.
130. Matsuo S, Shinozaki T, Takayama K, Minami S, Yamagushi S. A case of non-functioning islet cell tumor with hyperammonemia and hyperamylasemia. Surgery 1994; Suppl. 566: 149.
131. Galifer RB, Margueritte G, Balmes M, Barneon G, Rieu D. Ganglioneuroblastome de la tête du pancréas. Présentation d'un cas chez un garçon de 2 ans. Clin. Pediatr. 1983; 24: 396.
132. Cheslyn-Curtis S, Sitaram V, Williamson RCN. Management of non-functioning neuro-endocrine tumours of the pancreas. Br. J. Surg. 1993; 80: 625-7.
133. Rotman N, Sastre B, Fagnier PL. Medial pancreatectomy for tumors of the neck of the pancreas. Surgery 1993; 113: 532-5.
134. Marczell AP. Indications for fibrin sealing in pancreatic surgery with special regard to occlusion of a non-anastomosed pancreatic stump with fibrin sealant. Acta Chir. Austr. 1991; 3: 109-12.
135. Papachristou DN, Fortner JG. Pancreatic fistula complicating pancreatectomy for malignant disease. Br. J. Surg. 1981; 63: 238-40.
136. Arnold R, Neuhaus C, Benning R et al. Somatostatin analog, sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. World J. Surg. 1993; 17: 511-19.
137. Moertel CG, Leekpoulo M, Lipsitz S, Hahn RG, Klaasen D. Streptozocin-doxorubicin, streptozotocin-fluorouracil or chlorzotocin in the treatment of advanced islet cell carcinoma. N. Engl. J. Med. 1992; 326: 519-23.
138. Bengmark S, Ericsson M, Lunderquist A, Martensson, Nobin A, Sako M. Temporary liver dearterialization in patients with metastatic carcinoma disease. World J. Surg. 1982; 6: 46-53.
139. Ihse I, Persson B, Tibblin S. Neuroendocrine metastases of the liver. World J. Surg. 1995; 19: 76-82.
140. Allison DJ, Jordan H, Hennessy O. Therapeutic embolization of the hepatic artery: A review of 75 procedures. Lancet 1985; 1: 595-8.
141. Ruzniewski P, Rougier P, Roche A et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. Cancer 1993; 71: 2624-30.
142. Perry LJ, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994; 116: 1111-17.
143. O'Grady JG, Poison RJ, Rolles K, Calne RY, Williams R. Liver transplantation for malignant disease. Ann. Surg. 1988; 207: 373-9.
144. Makowka L, Tzakis AG, Mazzaferro V et al. Transplantation of the liver for metastatic endocrine tumors of the intestine and pancreas. Surg. Gynecol. Obstet. 1989; 168: 107-11.
145. Gulanikar AC, Kotylak G, Bittersuermann H. Does immunosuppression alter the growth of metastatic liver carcinoid after orthotopic liver transplantation? Transplant. Proc. 1991; 23: 2197-8.
146. Dousset B, Hoang JM, Icard P, Houssin D, Chapuis Y. Transplantation hépatique pour métastases de tumeur endocrine. Lyon Chir. 1994; 90: 36-7.
147. Pichlmayr R, Weimann A, Oldhafer KJ et al. Role of liver transplantation in the treatment of unresectable liver cancer. World J. Surg. 1995; 19: 807-13.
148. Anthuber M, Jauch KW, Briegel J, Groh J, Schildberg FW. Results of liver transplantation for gastroenteropancreatic metastases. World J. Surg. 1996; 20: 73-6.
149. Thompson NW, Eckhauser FE. Malignant islet-cell tumors of the pancreas. World J. Surg. 1984; 8: 940-51.
150. Norton JA, Sugarbaker PH, Doppman JL et al. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann. Surg. 1986; 203: 352-9.